ZNF266 and neoplasm: Patients overexpressing PRPF39, SPG7, PISD, TUBGCP6, RBM6, ZNF266, RBM39, DFNA5, and GUSB in the tumor tissues had significantly shorter survival duration than patients in the low-expression group.